Savara Inc
SVRA
View Detailed Chart
6.450USD
+0.050+0.78%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.78%
5 Days
+6.61%
1 Month
+20.34%
6 Months
+191.86%
Year to Date
+110.10%
1 Year
+96.65%
View Detailed Chart
TradingKey Stock Score of Savara Inc
Currency: USD Updated: 2025-12-26Key Insights
Savara Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 76/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.31.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Savara Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
10.313
Target Price
+59.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Savara Inc Highlights
StrengthsRisks
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -12.02, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 169.85M shares, decreasing 11.21% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 12.48K shares of this stock.
Savara Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Savara Inc Info
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Ticker SymbolSVRA
CompanySavara Inc
CEOPauls (Matthew)
Websitehttps://savarapharma.com/
FAQs
What is the current price of Savara Inc (SVRA)?
The current price of Savara Inc (SVRA) is 6.450.
What is the symbol of Savara Inc?
The ticker symbol of Savara Inc is SVRA.
What is the 52-week high of Savara Inc?
The 52-week high of Savara Inc is 7.005.
What is the 52-week low of Savara Inc?
The 52-week low of Savara Inc is 1.890.
What is the market capitalization of Savara Inc?
The market capitalization of Savara Inc is 1.11B.
What is the net income of Savara Inc?
The net income of Savara Inc is -95.88M.
Is Savara Inc (SVRA) currently rated as Buy, Hold, or Sell?
According to analysts, Savara Inc (SVRA) has an overall rating of Buy, with a price target of 10.313.
What is the Earnings Per Share (EPS TTM) of Savara Inc (SVRA)?
The Earnings Per Share (EPS TTM) of Savara Inc (SVRA) is -0.537.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
